The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A meta-analysis of the accuracy of a neuroendocrine tumor mRNA biomarker (NETest) in the blood.
 
Kjell E. Oberg
No Relationships to Disclose
 
Andrea Califano
No Relationships to Disclose
 
Jonathan R. Strosberg
Honoraria - Novartis; Novartis; Novartis; Novartis
Consulting or Advisory Role - Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Novartis; Novartis; Novartis; Novartis
Speakers' Bureau - Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon
Research Funding - Novartis; Novartis; Novartis; Novartis; Pharmacyclics; Pharmacyclics; Pharmacyclics; Pharmacyclics
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications
 
Steven M. Ma
No Relationships to Disclose
 
Ulrich-Frank Pape
Honoraria - Ipsen; Ipsen; Ipsen; Ipsen; Mundipharma; Mundipharma; Mundipharma; Mundipharma; Novartis; Novartis; Novartis; Novartis; Shire; Shire; Shire; Shire
Research Funding - Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Shire (Inst); Shire (Inst); Shire (Inst); Shire (Inst)
Travel, Accommodations, Expenses - Ipsen; Ipsen; Ipsen; Ipsen; Mundipharma; Mundipharma; Mundipharma; Mundipharma
 
Lisa Bodei
No Relationships to Disclose
 
Gregory Kaltsas
No Relationships to Disclose
 
Christos Toumpanakis
Honoraria - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; IPSEN; IPSEN; IPSEN; IPSEN; Novartis; Novartis; Novartis; Novartis
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Novartis; Novartis; Novartis; Novartis
 
James Goldenring
No Relationships to Disclose
 
Andreja Frilling
Honoraria - Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Advanced Accelerator Applications; Clifton Life Sciences; Clifton Life Sciences; Clifton Life Sciences; Clifton Life Sciences; IPSEN; IPSEN; IPSEN; IPSEN; Novartis; Novartis; Novartis; Novartis; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Research Funding - Ipsen; Ipsen; Ipsen; Ipsen
Travel, Accommodations, Expenses - IPSEN; IPSEN; IPSEN; IPSEN; Novartis; Novartis; Novartis; Novartis; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
 
Andrew Scott Paulson
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Actinium Pharmaceuticals; Actinium Pharmaceuticals; Actinium Pharmaceuticals; Immunomedics; Immunomedics; Immunomedics; Immunomedics
Honoraria - Cardinal Health; Cardinal Health; Cardinal Health; Cardinal Health
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Ipsen; Ipsen; Ipsen; Ipsen
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); incyte (Inst); incyte (Inst); incyte (Inst); incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen
 
Irvin Mark Modlin
No Relationships to Disclose